Drug Combo May Boost Survival for Tough-to-Treat Liver Cancers
TUESDAY, Feb. 9, 2021 (HealthDay News) — A new drug combination for advanced liver cancer can extend people’s lives substantially more than the long-standing drug of choice, new study findings confirm. The treatment involves two drugs approved to fight various cancers: bevacizumab (Avastin) and atezolizumab (Tecentriq). Avastin, an intravenous (IV)Continue Reading














